Maynard Um
-
-
-
-
-
-
-
Ribo and Madrigal hit first milestone in siRNA MASH drug program
-
-
-
-
-
-
-
Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
-
-
-
-
-
-
-
Truist on Madrigal Pharmaceuticals (MDGL): 'In-Licensed Asset Potentially Strengthens Pipeline'
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $579 at Wolfe Research
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL) Amid Rezdiffra Momentum
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Raised at TD Cowen on EU approval of Rezdiffra
-
429,884 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

